Anavex Life Sciences Corp. - Common Stock (NQ:AVXL)

1.820 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Anavex Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

December 03, 2025

From The Schall Law Firm

Via Business Wire

Anavex (AVXL) Q4 2025 Earnings Call Transcript ↗

November 25, 2025

Anavex (AVXL) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug ↗

November 25, 2025

Anavex ended the quarter with cash and cash equivalents of $102.6 million.

Via Stocktwits

Topics Artificial Intelligence

Anavex Life Sciences Corp (NASDAQ:AVXL) Surges on Better-Than-Expected Q4 2025 Earnings ↗

November 25, 2025

Anavex Life Sciences stock surges after reporting a smaller-than-expected Q4 2025 loss, beating EPS estimates and boosting investor confidence.

Via Chartmill

AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee ↗

November 10, 2025

Via Stocktwits

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update ↗

October 02, 2025

Via Stocktwits

What to Expect from Anavex Life Sciences's Earnings ↗

August 11, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

November 19, 2025

From Pomerantz LLP

Via GlobeNewswire

Anavex Retail Traders See Silver Lining In EMA Committee Postpones Alzheimer’s Drug Verdict: Delay 'Actually A Positive Sign' ↗

November 16, 2025

The CHMP issued a negative trend vote but postponed its final decision to December.

Via Stocktwits

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗

November 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Anavex Life Sciences Stock Falls After Hours On $300M Raise Plan; Retail Traders Think It’s A ‘Smart’ Move ↗

July 15, 2025

Via Stocktwits

An Overview of Anavex Life Sciences's Earnings ↗

May 12, 2025

Via Benzinga

Which stocks are moving on Friday? ↗

November 14, 2025

Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 14, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 14, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

Via Chartmill

Discover the top movers in Friday's pre-market session. ↗

November 14, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Via Chartmill

Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

November 14, 2025

Via Benzinga

AVXL Shares Slump Pre-market After EMA Committee Fails To Recommend Approval For Alzheimer’s Drug ↗

November 14, 2025

The CHMP released its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine was not included in the list.

Via Stocktwits

Anavex Stock Just Logged Its Worst Selloff In 2 Years — What Does EMA’s Oral Explanation Week Mean For Its Alzheimer’s Drug? ↗

November 14, 2025

The selloff comes as blarcamesine completed its oral explanation during the EMA’s Nov. 10–13 review window.

Via Stocktwits

Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group ↗

October 29, 2025

Anavex reports sustained cognitive benefits from oral blarcamesine, showing slower Alzheimer's progression and long-term efficacy over 144 weeks.

Via Benzinga

Anavex Life Sciences Stock Sparks Retail Banter On Hopes Of EMA Conditional Nod For Alzheimer's Drug, Big Pharma Tie-Up ↗

October 22, 2025

The report projected tens of billions in peak sales potential and said Anavex would likely require a big-pharma partnership to achieve full commercialization.

Via Stocktwits

Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study ↗

September 09, 2025

After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said.

Via Stocktwits

Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows ↗

August 20, 2025

Anavex published data showing blarcamesine prevented amyloid-related brain damage in mice, supporting SIGMAR1 as a target for Alzheimer's prevention.

Via Benzinga

Anavex Life Sciences: Early Blarcamesine Treatment Cuts Alzheimer's Progression by 20 Months ↗

July 31, 2025

Anavex reported that early use of blarcamesine in Alzheimer's trials led to sustained cognitive and functional improvements over 4 years.

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

July 02, 2025

Check out the top five trending stocks on Stocktwits on Wednesday as U.S. equity markets recover after taking a breather on Tuesday.

Via Stocktwits

Topics Government

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 28, 2025

Via Benzinga

Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years ↗

April 07, 2025

Anavex's blarcamesine shows sustained cognitive and functional benefit in early Alzheimer's patients after four years of continuous treatment.

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.